Patents Assigned to TARGETED THERAPEUTICS, LLC
  • Platelet targeted treatment
    Patent number: 10294291
    Abstract: The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 21, 2019
    Assignee: PLATELET TARGETED THERAPEUTICS, LLC
    Inventors: David A. Wilcox, Sandra L. Haberichter
  • Platelet targeted treatment
    Patent number: 9982034
    Abstract: The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: May 29, 2018
    Assignee: PLATELET TARGETED THERAPEUTICS, LLC
    Inventors: David A. Wilcox, Sandra L. Haberichter
  • Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
    Patent number: 9750728
    Abstract: A method of treating a patient in need of treatment for a disease selected from the group consisting of cancer, hamartoma syndrome and hereditary myopathy, the method comprising administering to the patient an effective dose of at least one PRCP and PREP dual antagonist pyridine compound of Formula (I) or an acid salt thereof, which can be administered either alone or in combination with at least one mTOR inhibitor.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 5, 2017
    Assignee: Targeted Therapeutics, LLC
    Inventors: Lei Duan, Victor Levenson, GuoGuang Ying
  • Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
    Patent number: 9545396
    Abstract: The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR antagonist, or jointly using PREP antagonist and mTOR antagonist, or jointly using PRCP-PREP dual antagonist and mTOR antagonist. In addition, the present invention also relates to a method for utilizing the pharmaceutical compositions to treat and prevent cancers and diseases related to insulin receptor substrate protein and PI3K/AKT/mTOR signal pathway.
    Type: Grant
    Filed: September 29, 2013
    Date of Patent: January 17, 2017
    Assignee: Targeted Therapeutics, LLC
    Inventors: Lei Duan, Victor Levenson, Guoguang Ying
  • METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING PI3K/AKT/MTOR SIGNALING PATHWAY
    Publication number: 20150328197
    Abstract: The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR antagonist, or jointly using PREP antagonist and mTOR antagonist, or jointly using PRCP-PREP dual antagonist and mTOR antagonist. In addition, the present invention also relates to a method for utilizing the pharmaceutical compositions to treat and prevent cancers and diseases related to insulin receptor substrate protein and PI3K/AKT/mTOR signal pathway.
    Type: Application
    Filed: September 29, 2013
    Publication date: November 19, 2015
    Applicant: TARGETED THERAPEUTICS, LLC
    Inventors: Lei Duan, Victor Levenson, Guoguang Ying